CD274 and neoplasm: In another Phase III trial (OAK) evaluating atezolizumab (an anti-PD-L1 monoclonal antibody), NSCLC patients with EGFR-mutated tumor also did not achieve OS benefit from the immunotherapy over docetaxel (11).